GlycoMimetics Inc (GLYC)
0.3158
0.00 (0.00%)
USD |
NASDAQ |
Nov 22, 11:00
GlycoMimetics Enterprise Value: 6.243M for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 6.243M |
| November 20, 2024 | 6.888M |
| November 19, 2024 | 10.05M |
| November 18, 2024 | 12.38M |
| November 15, 2024 | 12.43M |
| November 14, 2024 | 11.36M |
| November 13, 2024 | 11.53M |
| November 12, 2024 | 11.11M |
| November 11, 2024 | 12.54M |
| November 08, 2024 | 12.20M |
| November 07, 2024 | 12.70M |
| November 06, 2024 | 9.887M |
| November 05, 2024 | 10.76M |
| November 04, 2024 | 12.05M |
| November 01, 2024 | 10.28M |
| October 31, 2024 | 11.85M |
| October 30, 2024 | 15.05M |
| October 29, 2024 | 17.21M |
| October 28, 2024 | -3.546M |
| October 25, 2024 | -3.236M |
| October 24, 2024 | -3.184M |
| October 23, 2024 | -2.946M |
| October 22, 2024 | -3.752M |
| October 21, 2024 | -4.074M |
| October 18, 2024 | -4.177M |
| Date | Value |
|---|---|
| October 17, 2024 | -4.171M |
| October 16, 2024 | -4.274M |
| October 15, 2024 | -4.564M |
| October 14, 2024 | -4.809M |
| October 11, 2024 | -4.713M |
| October 10, 2024 | -5.087M |
| October 09, 2024 | -5.138M |
| October 08, 2024 | -4.538M |
| October 07, 2024 | -4.332M |
| October 04, 2024 | -4.087M |
| October 03, 2024 | -4.061M |
| October 02, 2024 | -4.461M |
| October 01, 2024 | -3.700M |
| September 30, 2024 | -3.494M |
| September 27, 2024 | -11.62M |
| September 26, 2024 | -11.39M |
| September 25, 2024 | -12.10M |
| September 24, 2024 | -11.78M |
| September 23, 2024 | -11.78M |
| September 20, 2024 | -11.76M |
| September 19, 2024 | -11.42M |
| September 18, 2024 | -11.81M |
| September 17, 2024 | -11.75M |
| September 16, 2024 | -11.93M |
| September 13, 2024 | -11.42M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-78.44M
Minimum
Mar 18 2020
182.94M
Maximum
Jan 23 2024
20.73M
Average
9.704M
Median
Oct 21 2020
Enterprise Value Benchmarks
| Biomarin Pharmaceutical Inc | 11.76B |
| Arbutus Biopharma Corp | 527.85M |
| Revance Therapeutics Inc | 649.94M |
| FibroGen Inc | 22.76M |
| Cidara Therapeutics Inc | -4.423M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -9.824M |
| Total Expenses (Quarterly) | 5.721M |
| EPS Diluted (Quarterly) | -0.15 |
| Earnings Yield | -196.3% |
| Normalized Earnings Yield | -183.66 |